Upadacitinib

證據等級: L5

預測適應症: 2 個

Upadacitinib: From Autoimmune/Inflammatory Disease to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome

One-Sentence Summary

Upadacitinib is a selective JAK1 inhibitor originally developed for autoimmune and inflammatory conditions; its detailed original indication and mechanism-of-action data are not yet available in this evidence pack. The TxGNN model assigns a high similarity score to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome, a rare congenital skeletal-ocular malformation syndrome, but this prediction is currently supported by zero clinical trials and zero publications, and the evidence pack's own mechanistic analysis flags it as likely model noise rather than a biologically plausible hypothesis.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (JAK1 inhibitor class, typically autoimmune/inflammatory disease)
Predicted New Indication	Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
TxGNN Prediction Score	99.61%
Evidence Level	L5
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (original_moa is unpopulated). Based on the repurposing rationale provided, upadacitinib is a selective JAK1 inhibitor that modulates cytokine signaling (IL-6, IFN, IL-2 family, etc.), consistent with its known use in autoimmune/inflammatory disease.

The predicted indication — colobomatous microphthalmia-rhizomelic dysplasia syndrome — is a rare congenital disorder driven by embryonic developmental gene defects, not by chronic inflammatory or JAK-STAT-mediated pathology. The evidence pack's own mechanistic assessment states there is no known biological link between JAK1 inhibition and this structural developmental syndrome, and attributes the high TxGNN score to graph-embedding similarity artifacts rather than a genuine pharmacological hypothesis.

A second candidate, brachydactyly-syndactyly syndrome (score 99.58%, rank 5278), shows the same pattern: a limb-development disorder (typically HOX gene / BMP-Hedgehog pathway related) with no plausible connection to JAK1 inhibition, and no supporting trials or literature. Both top-ranked predictions in this batch should be treated as low-confidence model artifacts rather than actionable repurposing candidates.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Germany Market Information

Upadacitinib currently holds no marketing authorization on record in this jurisdiction (market status: Not Marketed, 0 authorizations). No product/license data available.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA label warnings/contraindications and DDI data are currently missing — see DG001, a Blocking-severity gap that prevents S1 safety pre-assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication has no supporting clinical trials or literature (Evidence Level L5), and the evidence pack's own mechanistic analysis assesses the drug-disease link as biologically implausible, likely reflecting embedding-similarity noise rather than a genuine signal. Combined with a Blocking-severity safety data gap (TFDA label unavailable) and missing MOA/original-indication data, there is insufficient basis to advance this candidate.

To proceed, the following is needed:

TFDA label (warnings, contraindications) to resolve DG001 (Blocking)
Confirmed original MOA and approved indication(s) via DrugBank/regulatory source (DG002)
Independent mechanistic or preclinical rationale linking JAK1 inhibition to this syndrome before allocating further review resources
If no such rationale emerges, deprioritize both rank-1 and rank-2 candidates as low-value predictions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.